Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
about
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsEmerging Techniques in Brain Tumor Imaging: What Radiologists Need to KnowIntegrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.Detecting tumor progression in glioma: Current standards and new techniques.Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastomaMR-guided radiation therapy: transformative technology and its role in the central nervous system.Advances in neuro-oncology imaging.Current Clinical Brain Tumor ImagingDiffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed GlioblastomaMean apparent diffusion coefficient values in defining radiotherapy planning target volumes in glioblastoma.Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort.Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.Quantitative Imaging Biomarkers for Risk Stratification of Patients with Recurrent Glioblastoma Treated with Bevacizumab.Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas.Predictive imaging marker of bevacizumab efficacy: perfusion MRI.Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.Radiomics in Brain Tumor: Image Assessment, Quantitative Feature Descriptors, and Machine-Learning Approaches.Glioma.The Added Prognostic Value of Metabolic Tumor Size on FDG-PET at First Suspected Recurrence of Glioblastoma Multiforme.Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas.Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.Imaging in neuro-oncology.
P2860
Q26853308-E933B5C3-3111-4902-B4B7-0F2992A81F47Q28068259-CEE76174-C20F-4E90-A42C-D98908DE1826Q31113520-D6737996-9FF0-414A-B0F9-51C4E2F637F9Q31132701-57AF4F53-FCC2-4991-B62A-827E14BDB1BEQ35815295-73CD18A7-A0A5-43D1-BB7A-6A551B855D7BQ36336361-64631980-AEF4-4ED4-B3C1-D201C020EA33Q36339461-CE3EF135-5077-412A-9502-25EB8DC513A8Q36367172-5DBC3AF7-0DE9-40F4-B75D-BE82A9113E3CQ36424068-009F76B7-9FBF-415A-A9CD-884EBCAC74FEQ36427409-579B34A8-3FA4-4026-B706-1C07141662D5Q36427538-A4486E67-0806-4200-B779-57D2A731CA2BQ37452768-D1C83427-BA87-48E5-9C8E-C734733943CCQ38706148-ED32C671-ACD6-480C-82A7-51B421725F3EQ38747896-65159C8A-C8FE-4F8F-B06B-C5D3BEDE373DQ38789124-446BDCAD-1343-4B3A-BBA6-0189D8DA4F6EQ39435280-3A21353D-5791-47C1-A7BF-7D7E1FB3541DQ39510956-DBA11B17-2831-4F3C-ABF4-00798DA7A89EQ41232766-1CE3EF16-7132-4FF7-8CE2-09ED99554522Q42364159-D77552B0-213A-4D98-81E2-E0E57029A689Q42702318-D6C0420B-C427-4AED-93FC-3AA16B1AC8EEQ45945185-20FEDC2C-8C12-47DD-9976-736B7CBF4BDFQ46820292-1ACFB646-7B52-4117-9B91-63ACC6CAC8E5Q47281917-4A345FD2-2464-4953-9FA2-0BF35AD7BF11Q48168860-A1A2F46F-BAC8-4314-A151-24BCD6EA2DFBQ48245198-C2A92C45-BEE2-48A7-8992-E8F7B6AD3CC0Q48541561-0A2D13A6-E64B-49D8-ACDB-4DE50F85B5AFQ48930260-992AD1F8-9EC3-4B92-8106-FB99BC4A321CQ52149377-25B79162-82B8-4331-8534-FF17CCED03EFQ54973707-B0CCE689-3ABF-404D-B68F-2FA65B5107B5
P2860
Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Pretreatment ADC histogram ana ...... apy in recurrent glioblastoma.
@en
Pretreatment ADC histogram ana ...... apy in recurrent glioblastoma.
@nl
type
label
Pretreatment ADC histogram ana ...... apy in recurrent glioblastoma.
@en
Pretreatment ADC histogram ana ...... apy in recurrent glioblastoma.
@nl
prefLabel
Pretreatment ADC histogram ana ...... apy in recurrent glioblastoma.
@en
Pretreatment ADC histogram ana ...... apy in recurrent glioblastoma.
@nl
P2093
P2860
P921
P356
P1476
Pretreatment ADC histogram ana ...... apy in recurrent glioblastoma.
@en
P2093
B M Ellingson
D C Woodworth
P L Nghiemphu
R J Harris
S Sahebjam
T F Cloughesy
P2860
P304
P356
10.3174/AJNR.A3748
P577
2013-10-17T00:00:00Z